BFEC
RXRX icon

Benjamin F. Edwards & Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1.27M Buy
169,900
+167,302
+6,440% +$1.46M 0.02% 465
2024
Q1 		$26K Buy
+2,598
New +$28.9K ﹤0.01% 1468

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Benjamin F. Edwards & Company's RXRX Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Recursion Pharmaceuticals (RXRX) stake by 6,440% in Q2 2024, buying an estimated $1.46M and bringing the position to 169,900 shares worth $1.27M. The position accounts for 0.02% of the portfolio, ranked #465.

Benjamin F. Edwards & Company first reported a position in RXRX in Q1 2024 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Benjamin F. Edwards & Company held 169,900 shares of Recursion Pharmaceuticals worth $1.27M as of Q2 2024.
  • Benjamin F. Edwards & Company bought 167,302 Recursion Pharmaceuticals shares in Q2 2024, an estimated $1.46M.
  • Recursion Pharmaceuticals made up 0.02% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #465 holding.
  • Benjamin F. Edwards & Company first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.